DP
OLMA icon

Diadema Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Diadema Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Sell
84,000
-12,100
-13% -$269K 0.21% 80
2025
Q4 		$2.4M Buy
96,100
+5,600
+6% +$99.6K 0.41% 54
2025
Q3 		$886K Buy
+90,500
New +$543K 0.23% 91

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Diadema Partners's OLMA Position: Q3 2025 in Review

Diadema Partners sold out of Olema Pharmaceuticals (OLMA) in Q3 2025, closing a stake of 253,657 shares — an estimated $1.52M sold.

Diadema Partners first reported a position in OLMA in Q1 2025 and held it in 2 quarters. The position peaked at $1.08M in Q2 2025. 126 funds tracked by Wall St. Rank hold OLMA as of Q3 2025.

  • Diadema Partners reported no remaining Olema Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Diadema Partners sold 253,657 Olema Pharmaceuticals shares in Q3 2025, an estimated $1.52M.
  • Diadema Partners first reported a position in Olema Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Diadema Partners's Olema Pharmaceuticals position peaked at $1.08M in Q2 2025.
  • 126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2025.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.